# mRECIST Outcomes in EMERALD-1: A Phase 3, Randomized, Placebo-Controlled Study of Transarterial Chemoembolization plus Durvalumab with or without Bevacizumab in Participants with Embolization-Eligible Hepatocellular Carcinoma

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/mrecist-outcomes-in-emerald-1-a-phase-3-randomized-placebo-controlled-study-of/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Bruno Sangro,Masashi Kudo,Joseph P. Erinjeri,Songbing Qin,Zhenggang Ren,Stephen L. Chan,Yosuke Arai,Jeong Heo,Adil Mai,Felipe Penagos,Yamil Alonso Lopez Chuken,Je‐Hyun Yoon,Won Young Tak,Tanita Suttichaimongkol,Mohamed Bouattour,Shi‐Ming Lin,M. Żotkiewicz,Sajid Ali,G.J. Cohen,Riccardo Lencioni |
| Citations | 1 |
| DOI | 10.1016/j.ijrobp.2024.07.977 |
| Fields | Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W4402909603 |
| Type | article |
| Year | 2024 |

## Paper authors

- [Adil Mai](https://scholariq.org/researchers/adil-mai/)

## Paper journal

- [International Journal of Radiation Oncology*Biology*Physics](https://scholariq.org/journals/international-journal-of-radiation-oncology-biology-physics/)

## Paper primary topic

- [Hepatocellular Carcinoma Treatment and Prognosis](https://scholariq.org/topics/hepatocellular-carcinoma-treatment-and-prognosis/)

## Paper topics

- [Hepatocellular Carcinoma Treatment and Prognosis](https://scholariq.org/topics/hepatocellular-carcinoma-treatment-and-prognosis/)
- [Renal cell carcinoma treatment](https://scholariq.org/topics/renal-cell-carcinoma-treatment/)
- [Lymphoma Diagnosis and Treatment](https://scholariq.org/topics/lymphoma-diagnosis-and-treatment/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.